MedTrace Logo

Primary Hyperparathyroidism and Gut Microbiota

NCT04948671 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-04-13

No results posted yet for this study

Summary

Primary hyperparathyroidism (PHPT) may induce bone loss according with the composition of the gut microbiota (GM), and particularly, on the presence of intestinal bacterial that induce T helper 17 differentiation.

We will evaluate GM composition and evaluate how GM modulates immune system in patients affected by PHPT with or without skeletal involvement. Furthermore, we will unravel the causal relationship between GM composition and T cells activation.

Upon success, HYPOGEUM will show that GM sequencing is a screening tool to identify PHPT that will lose bone, suggesting novel strategies with antimicrobial treatments to prevent bone loss.

HYPOGEUM will yield essential data to understand and prevent skeletal complications associated with PHPT.

Conditions

  • Hyperparathyroidism, Primary

Interventions

OTHER

there will be no intervention, this is an observational study

this is an observational study

Sponsors & Collaborators

  • The Novartis Foundation

    collaborator OTHER

  • Centre Hospitalier Universitaire Vaudois

    lead OTHER

Principal Investigators

  • Patrizia D'amelio, MD, PhD · Service de gériatrie et réadaptation gériatrique-CHUV

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2026-02-07
Completion
2026-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948671 on ClinicalTrials.gov